Vaxcyte, INC Form 4 insider transactions

Grant Pickering, CHIEF EXECUTIVE OFFICER and a Director of Vaxcyte, Inc., reported a transaction in 17,056 shares of common stock on September 8, 2026.

Andrew Guggenhime, PRESIDENT AND CFO of Vaxcyte, Inc., reported a transaction in 7,155 shares of common stock on September 8, 2026.

Harpreet S. Dhaliwal, Chief Technical Ops Officer of Vaxcyte, Inc., reported a transaction in 7,651 shares of common stock on September 8, 2026.

Elvia Cowan, SVP, Finance & CAO of Vaxcyte, Inc., reported a transaction in 1,327 shares of common stock on September 8, 2026.

Jim Wassil, EVP, Chief Scientific Ofc, COO of Vaxcyte, Inc., sold 2,715 shares of common stock on September 4, 2026.

Luis Jodar, Chief Medical Officer of Vaxcyte, Inc., reported multiple transactions in common stock on September 4, 2026.

Jim Wassil, CHIEF OPERATING OFFICER of Vaxcyte, Inc., sold 3,477 shares of common stock on August 31, 2026.

Grant Pickering, CHIEF EXECUTIVE OFFICER and a Director of Vaxcyte, Inc., reported multiple transactions in common stock on August 31, 2026.

Andrew Guggenhime, PRESIDENT AND CFO of Vaxcyte, Inc., reported multiple transactions in common stock on August 31, 2026.

Harpreet S. Dhaliwal, Chief Technical Ops Officer of Vaxcyte, Inc., reported multiple transactions in common stock on August 31, 2026.

Elvia Cowan, SVP, Finance & CAO of Vaxcyte, Inc., reported multiple transactions in common stock on August 31, 2026.

Harpreet S. Dhaliwal, Chief Technical Ops Officer of Vaxcyte, Inc., sold 17,000 shares of common stock on August 5, 2026 for $55.00 per share.

Jim Wassil, CHIEF OPERATING OFFICER of Vaxcyte, Inc., sold 2,250 shares of common stock on August 3, 2026.

Andrew Guggenhime, PRESIDENT AND CFO of Vaxcyte, Inc., sold 10,000 shares of common stock on August 3, 2026.

Grant Pickering, CHIEF EXECUTIVE OFFICER and a Director of Vaxcyte, Inc., sold 18,198 shares of common stock on July 27, 2026.

John Markels, a Director of Vaxcyte, Inc., received 23,029 shares of common stock on July 16, 2026.

Vaxcyte, Inc. reports that President and CFO Andrew Guggenhime sold 10,000 shares of common stock under a pre-arranged trading plan.

Vaxcyte, Inc. (PCVX) Chief Operating Officer Jim Wassil reported transactions involving the sale of company stock under a pre-arranged trading plan.

Vaxcyte, Inc. CEO Grant Pickering has sold a significant number of common shares under a pre-arranged trading plan.

Vaxcyte CEO Grant Pickering reported transactions involving company stock, including the acquisition of shares at $1.79 and the disposition of shares at $52.51, executed under a Rule 10b5-1 trading plan.

Vaxcyte, Inc. reports insider transactions by President and CFO Andrew Guggenhime, involving the acquisition and disposition of common stock.

Vaxcyte, Inc. reports a Form 4 filing detailing director Carlos V. Paya's acquisition of restricted stock units and stock options.

Vaxcyte, Inc. reports that Director Olivier Brandicourt acquired 2,194 shares of common stock and was granted options for 11,034 shares.

Vaxcyte Director John Furey reported the acquisition of 2,265 shares of common stock and 11,389 stock options on June 15, 2026.

Vaxcyte, Inc. Director Jacks Lee acquired 2,265 shares of common stock and was granted options for 11,389 shares.

Vaxcyte, Inc. director Halley E. Gilbert reported transactions involving restricted stock units and stock options on June 15, 2026.

Vaxcyte, Inc. reports that Director Teri Loxam acquired shares and stock options on June 15, 2026.

Vaxcyte, Inc. Director Anne S. Drapeau reported a transaction involving the acquisition of 2,265 shares of common stock and the grant of stock options for 11,389 shares.

Vaxcyte, Inc. Director Heath Lukatch reported the acquisition of 2,265 shares of common stock and the grant of stock options for 11,389 shares.

Vaxcyte, Inc. reports that Chief Operating Officer Jim Wassil sold a significant number of company shares through a pre-arranged trading plan.